Immunotherapy

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
Bilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, Tharakeswara K Bathala, Devaki Shilpa Surasi, Jianjun Gao, Amishi Shah, Matthew T Campbell, Pavlos Msaouel, Sangeeta Goswami, Jennifer Wang, Amado J Zurita, Eric Jonasch, Paul G Corn, Ana M Aparicio, Arlene O Siefker-Radtke, Padmanee Sharma, Sumit K Subudhi, Nizar Tannir

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002850; DOI: 10.1136/jitc-2021-002850
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
Dongqiang Zeng, Jiani Wu, Huiyan Luo, Yong Li, Jian Xiao, Jianjun Peng, Zilan Ye, Rui Zhou, Yunfang Yu, Gaofeng Wang, Na Huang, Jianhua Wu, Xiaoxiang Rong, Li Sun, Huiying Sun, Wenjun Qiu, Yichen Xue, Jianping Bin, Yulin Liao, Nailin Li, Min Shi, Kyoung-Mee Kim, Wangjun Liao

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002467; DOI: 10.1136/jitc-2021-002467
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Niklas Klümper, Damian J Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michèle J Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan, Julie Steinestel, Konrad Steinestel, Ralph M Wirtz, Danijel Sikic, Markus Eckstein, Glen Kristiansen, Marieta Toma, Michael Hölzel, Manuel Ritter, Sebastian Strieth, Jörg Ellinger, Dimo Dietrich

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002949; DOI: 10.1136/jitc-2021-002949
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
Michael P Gustafson, Courtney M Wheatley-Guy, Allison C Rosenthal, Dennis A Gastineau, Emmanuel Katsanis, Bruce D Johnson, Richard J Simpson

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e001872; DOI: 10.1136/jitc-2020-001872
Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors
Laura K Fogli, Rosemarie Aurigemma, Connie L Sommers, Anju Singh, Kasia Bourcier, Marc S Ernstoff

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003048; DOI: 10.1136/jitc-2021-003048
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer
Zongren Wang, Xueling Zhang, Wuguo Li, Qiao Su, Zhaoyang Huang, Xinyao Zhang, Haiqi Chen, Chengqiang Mo, Bin Huang, Wei Ou, Junxing Chen, Guangyin Zhao, Lingwu Chen, Lan Shao

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e001758; DOI: 10.1136/jitc-2020-001758
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
Chunwan Lu, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel, Thomas Albers, Jennifer L Waller, Huidong Shi, Kebin Liu

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002624; DOI: 10.1136/jitc-2021-002624
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo, Karisa C Schreck, Wei Fu, Chen Hu, Alexander Carvajal-Gonzalez, Roisin M Connolly, Cesar A Santa-Maria, Evan J Lipson, Matthias Holdhoff, Patrick M Forde, Christopher Douville, Joanne Riemer, Amanda Barnes, Kristin J Redmond, Lawrence Kleinberg, Brandi Page, Nafi Aygun, Kenneth W Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Arun Venkatesan, Julie R Brahmer, Stuart A Grossman

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002473; DOI: 10.1136/jitc-2021-002473
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Lele Zhang, Jiacheng Huang, Xiaona Chen, Caixu Pan, Yong He, Rong Su, Danjing Guo, Shengyong Yin, Shuai Wang, Lin Zhou, Jianxiang Chen, Shusen Zheng, Yiting Qiao

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003132; DOI: 10.1136/jitc-2021-003132
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Takashi Nakamura, Takanori Sato, Rikito Endo, Shun Sasaki, Naomichi Takahashi, Yusuke Sato, Mamoru Hyodo, Yoshihiro Hayakawa, Hideyoshi Harashima

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002852; DOI: 10.1136/jitc-2021-002852

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages